Day One Biopharmaceuticals: Strong Potential, Price Drop Opportunity, Some ConcernsSeeking Alpha • 04/07/23
Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate ProgressGlobeNewsWire • 03/06/23
Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade GliomaGlobeNewsWire • 01/08/23
Day One to Participate in the Piper Sandler 34th Annual Healthcare ConferenceGlobeNewsWire • 11/17/22
Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual MeetingGlobeNewsWire • 11/11/22
Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101)GlobeNewsWire • 10/17/22
Foundation Medicine and Day One Biopharmaceuticals Announce Global Collaboration to Advance Pediatric Cancer CareBusiness Wire • 09/21/22
Day One to Participate in the 2022 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewsWire • 08/02/22
Wall Street Analysts Think Day One Biopharmaceuticals, Inc. (DAWN) Could Surge 85%: Read This Before Placing a BetZacks Investment Research • 07/18/22
Day One Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 06/21/22
Day One Biopharmaceuticals: Early Pediatric Brain Cancer Data Makes Tentative Buy CaseSeeking Alpha • 06/15/22